December 12, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Tamika N. Sheppard
| Re: | Acrivon Therapeutics, Inc. | |||
| Registration Statement on Form S-3 | ||||
| File No. 333-275854 | ||||
| Acceleration Request | ||||
| Requested Date: December 15, 2023 | ||||
| Requested Time: 4:30 P.M., Eastern Time | ||||
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Acrivon Therapeutics, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-275854 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:30 P.M., Eastern Time, on December 15, 2023, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.
We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Asher Rubin of Sidley Austin LLP at (410) 559-2881 or arubin@sidley.com.
| Very truly yours, |
| /s/ Peter Blume-Jensen |
| Peter Blume-Jensen |
| President and Chief Executive Officer |
| Acrivon Therapeutics, Inc. |
| cc: | Mary-Alice Miller, General Counsel and Corporate Secretary |
Asher Rubin, Sidley Austin LLP
Istvan Hajdu, Sidley Austin LLP